Sangamo Therapeutics Inc.Find Ratings Reports
SANGAMO THERAPEUTICS INC's gross profit margin for the first quarter of its fiscal year 2018 has significantly increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth.
At the same time, stockholders' equity ("net worth") has greatly increased by 45.09% from the same quarter last year.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY18||Q1 FY17|
|Net Sales ($mil)||12.64||3.43|
|Net Income ($mil)||-20.19||-16.63|
|Balance Sheet||Q1 FY18||Q1 FY17|
|Cash & Equiv. ($mil)||0.0||129.27|
|Total Assets ($mil)||281.17||146.81|
|Total Debt ($mil)||0.0||3.93|
|Profitability||Q1 FY18||Q1 FY17|
|Gross Profit Margin||-166.15||-481.49|
|Return on Assets||-20.67||-48.9|
|Return on Equity||-31.87||-57.12|
|Debt||Q1 FY18||Q1 FY17|
|Share Data||Q1 FY18||Q1 FY17|
|Shares outstanding (mil)||85.6||71.75|
|Div / share||0.0||0.0|
|Book value / share||2.13||1.75|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2472781.0||1824377.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 7.65 indicates a significant premium versus the S&P 500 average of 3.22 and a significant discount versus the industry average of 14.54. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, SANGAMO THERAPEUTICS INC proves to trade at a discount to investment alternatives within the industry.
|SGMO NM||Peers 40.22||SGMO NA||Peers 49.50|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
SGMO's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|SGMO NM||Peers 52.34||SGMO NA||Peers 0.38|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
SGMO's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|SGMO 7.65||Peers 14.54||SGMO 31.38||Peers 34.32|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
SGMO is trading at a significant discount to its peers.
Average. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
SGMO is expected to keep pace with its peers on the basis of earnings growth.
|SGMO 30.48||Peers 71.07||SGMO 142.57||Peers 332.84|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
SGMO is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
SGMO significantly trails its peers on the basis of sales growth